MLI Certified

On-Demand Activities

More results...

Therapeutics Areas

Learner Specialties

Expires After

On-Demand

Time Well Spent: Treating Obesity and Diabetes

Credit: 1.0hr(s)
AAPA, CME, NCPD

November 10, 2023 —
November 9, 2024

Therapeutic Areas: Family Medicine / Primary Care
Specialties: Diabetes, Obesity, Primary Care
Location: Internet Activity Enduring

View Course Description

Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).

On-Demand

Episode 2 of 4 - Biomarker Testing: Shaping Personalized Medicine

Credit: 0.15hr(s)
NCPD

November 22, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

For non-small cell lung cancer (NSCLC), the rates of 5-year survival have improved significantly over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. With an expansion of the treatment arsenal, it is up to clinicians to decipher the latest guideline recommendations and apply evolving clinical evidence to ensure optimal treatment selection and patient education. Join us for the second episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care in which our expert faculty explore the implications of test results for prognosis and discuss methods to empower patients to engage in their care.

On-Demand

The Evolution of HCT, Part 5: Shared Care

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.

On-Demand

Episode 1 of 4 - The Evolution of Biomarker Testing: Revolutionizing Treatment of NSCLC

Credit: 0.30hr(s)
NCPD

November 22, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

Biomarker testing can have a significant impact on the treatment plan of patients with non-small cell lung cancer (NSCLC). In this first episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care, expert faculty apply the latest clinical guidelines and give practical tips on breaking down barriers for oncology teams to successfully implement biomarker testing for NSCLC patients, including those in underserved populations.

On-Demand

New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease

Credit: 1.00hr(s)
AAPA, CME, CPE, IPCE, NCPD

May 31, 2023 —
May 30, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: CAR T-Cell Therapy, Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM). This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.

On-Demand

The Evolution of HCT, Part 2: Eligibility

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 2 in a 5-part series, covering advances that have expanded eligibility for HCT and considerations for who is a candidate.

On-Demand

Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment

Credit: 0.30hr(s)
AAPA, CME, CPE, NCPD

November 29, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing

On-Demand

Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

January 26, 2023 —
February 8, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss: The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies Prevention and management strategies for adverse events associated with BCMA agents The unmet need for representation in clinical trials

On-Demand

Setting Up Patients for HCT and Cell Therapy Success

Credit: 1.00hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

This self-guided course provides practical recommendations and guidance on what hematology/oncology practices can do to improve patient experience and outcomes before their patient reaches a transplant center for consultation for Hematopoietic Cell Transplantation (HCT).

On-Demand

Transforming Relapsed/Refractory MCL: Exploring New Options for Your Patients

Credit: 1.0hr(s)
CME, EBAH, ECMEC

June 28, 2023 —
June 28, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: Lymphoma, Mantle Cell Lymphoma
Location: Internet Activity Enduring

View Course Description

Treatment for R/R MCL is complicated, as the disease typically presents in elderly, unfit patients; however, emerging targeted therapy options have shown great promise based on excellent results in clinical trials. In this activity, a taped version of the live symposium at the 17th Annual International Conference on Malignant Lymphoma, expert faculty present therapeutic options, established by evidence-based practice guidelines, for patients with R/R MCL. Symposium learners voted on patient demographics and parameters such as treatment, dosing frequency, and adverse events. The experts crafted their lecture to follow thheir suggestions allowing the case studies to reflect the patients the learners see. The activity concludes with a discussion on engagement between healthcare providers and patients to improve clinical outcomes.

On-Demand

GVHD 5 - ECHO Program: Atypical Manifestations of Chronic GVHD

Credit: 1.0hr(s)

December 8, 2022 —
December 8, 2023

Therapeutic Areas: Dermatology, Family Medicine / Primary Care, Internal Medicine, Rheumatology
Specialties: Primary Care
Location: Internet Activity Enduring

View Course Description

The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care. The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients. Questions and comments from the learners will be encouraged to facilitate discussion.

On-Demand

Build Your Own Case Study | Obesity: Treating the Whole Patient

Credit: 1.0hr(s)
AAPA, CME, CPE, NCPD

April 27, 2023 —
April 26, 2024

Therapeutic Areas: Endocrinology, Family Medicine / Primary Care
Specialties: Obesity
Location: Internet Activity Enduring

View Course Description

Obesity is a chronic, progressive, relapsing disease that impacts health and quality of life. In individuals with obesity, there are many contributors to its development and persistence, including lifestyle, social, and economic factors. If left untreated, obesity can be a primary driver of serious health consequences. By treating obesity first, complications arising from obesity may improve or resolve. Given the severity of the disease, there is a need for clinicians in primary and specialty care settings to diagnose and treat obesity so that patients can receive the most appropriate treatment and care. Evidence-based treatment options, including anti-obesity medications, are emerging for adults and children. In this immersive virtual Build Your Own Case Study | Obesity: Treating the Whole Patient, navigate through your toughest clinical challenges while leading experts reinforce essential topics, such as: Medical consequences and comorbidities of obesity Application of adiposity measures, including BMI and waist circumference Latest clinical evidence of new and emerging anti-obesity medications Best practices in shared decision-making and starting the conversation with your patients

On-Demand

Episode 1 of 3 - What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL

Credit: 0.30hr(s)
AAPA, CME, CPE, NCPD

December 1, 2023 —
December 14, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
Location: Internet Activity Enduring

View Course Description

The treatment landscape in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. However, keeping up with the latest clinical evidence and updates to the clinical guidelines on these agents can be challenging for busy clinicians and their care teams. In this first episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, sit in on a conversation with our expert faculty as they discuss the new standard of care for CLL and SLL and how to apply this care transition to your patients and clinic.

On-Demand

The Evolution of HCT, Part 3: Donor Availability

Credit: 0.75hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.

On-Demand

Episode 3 of 3 - Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs

Credit: 0.30hr(s)
AAPA, CME, CPE, NCPD

December 1, 2022 —
December 14, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
Location: Internet Activity Enduring

View Course Description

In the advent of novel targeted therapies for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), clinicians must consider the potential of adverse events (AEs) that can affect patient outcomes. In the last episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, our expert faculty will engage in an interactive discussion on AE-management to promote optimal treatment-decision making for clinicians. In addition, learn tips to on how to counsel your patients on monitoring their symptoms to support timely and effective care.

On-Demand

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

February 17, 2023 —
February 16, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: NSCLC, Oncology
Location: Internet Activity Enduring

View Course Description

This educational initiative is designed for community-based oncology clinicians (physicians, nurse practitioners [NPs], physician assistants [PAs], pharmacists, and nurses) to enhance outcomes for individuals with who provide care for individuals with mNSCLC. This interactive online activity uses the game-based platform Kahoot! to test participant ability to identify and apply key learning points while competing against their colleagues. Expert faculty will discuss the emerging efficacy and safety data for CTLA-4 inhibitor combination regimens in metastatic NSCLC (mNSCLC) and explore strategies to identify patients who would most benefit from these therapies through the use of biomarkers. Additionally, there will be an in-depth discussion regarding approaches to effectively collaborate with other clinicians and mNSCLC patients to provide cost-effective, equitable, and inclusive care for patients of all socioeconomic and racial/ethnic backgrounds. Join us for Part 2 of this question and answer based educational activity, Improving Survival in First-line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice to apply the evidence to real-world patient cases!

On-Demand

Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

February 2, 2023 —
February 8, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

Despite treatment advances, most patients with multiple myeloma will progress after administration to the standard of care regimens, including proteasome inhibitors, immunomodulatory agents, and chemotherapy. Therefore, it is important for the continual development of novel and effective therapies, especially for underserved communities. Agents targeting B-cell maturation antigen (BCMA) have shown substantial therapeutic responses. Join us in the 2nd episode of the 3-part Med Table Talk® on Navigating the Evidence: Pathways for New and Emerging BCMA Therapies as our expert faculty discuss the safety and efficacy of the emerging BCMA agents. In addition, don’t miss out on the featured conversation with Dr. Saad Usmani, MD, as he discusses practical strategies to improve diversity in clinical trial enrollment.

On-Demand

Demystifying the Evolving Science and Potential Role of Incretins in T2D

Credit: 1.25hr(s)
CME

December 7, 2023 —
January 2, 2024

Therapeutic Areas: Diabetes, Endocrinology
Specialties: Diabetes, Endocrinology, Obesity
Location: Internet Activity Enduring

View Course Description

Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs. What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the IDF World Diabetes Congress on December 6, 2022.

On-Demand

Episode 4 of 4 - Practical Strategies for Preventing and Mitigating Toxicities of Targeted Therapy

Credit: 0.30hr(s)
NCPD

November 29, 2022 —
November 28, 2023

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Biomarkers, NSCLC
Location: Internet Activity Enduring

View Course Description

Despite advances with targeted therapies, adverse events (AEs) must be identified and managed for optimal treatment response, clinical outcomes, and quality of life for patients with non-small cell lung cancer (NSCLC). Join us for the final episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC: Improving Collaboration, Communication, and Care, in which our expert faculty have a candid conversation about mitigating common AEs associated with targeted therapies and provide strategies for engaging underserved patients in the prevention and monitoring of these potential toxicities.

On-Demand

Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy

Credit: 0.50hr(s)
AAPA, CME, CPE, NCPD

February 8, 2023 —
February 8, 2024

Therapeutic Areas: Hematologic Oncology, Oncology
Specialties: Multiple Myeloma
Location: Internet Activity Enduring

View Course Description

Treatment strategies for relapsed/refractory multiple myeloma (RRMM) are inevitably complex as oncology teams must consider patient-, treatment-, and disease-related factors in their decision-making. Tune into the last episode of the Med Table Talk® Series on Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy

On-Demand

Bridging the Gap to Reach Treatment Goals in DLBCL

Credit: 1.0hr(s)
AAPA, CME, CPE, NCPD

March 15, 2023 —
February 28, 2024

Therapeutic Areas: Hematologic Oncology, Hematology
Specialties: CAR T-Cell Therapy, Lymphoma
Location: Internet Activity Enduring

View Course Description

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, which typically occurs in patients over the age of 60 years. While chemoimmunotherapy (R-CHOP) has been considered the first line treatment option, approximately 40% of patient with DLBCL will fail to respond and experience a relapse. Autologous hematopoietic stem cell transplantation (AHCT) has been used as treatment for patients who experience a relapse; however, many patients are ineligible for the procedure due to age, comorbidities, or resistance to second-line chemoimmunotherapy. Novel treatment options have thus been introduced to the treatment landscape of DLBCL, including chimeric antigen receptor T-cell therapy (CAR T) with trial results displaying sustained remissions for relapsed patients. Because the options for treatment of DLBCL have changed rapidly, it is important for treating physicians to be aware of the options that are available as well as assist them in overcoming barriers that may impact their treatment. Join us for this educational Med Table Talk® LIVE on Bridging the Gap to Reach Treatment Goals in DLBCL as our experts have a candid conversation about the available treatment options for DLBCL, how cellular therapists and community physicians must communicate to ensure adequate care between referring and treating physicians, and how to recognize and address common treatment barriers. This taped satellite symposium was derived from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCTTM and CIBMTR® on February 18, 2023.

On-Demand

The Evolution of HCT, Part 4: Addressing Barriers

Credit: 0.50hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 4 in a 5-part series, examining major barriers to HCT and ways to overcome them.

On-Demand

The Evolution of HCT, Part 1: Basics and Outcomes

Credit: 1.50hr(s)
CME, NCPD

February 22, 2023 —
February 21, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
Specialties: Bone Marrow Transplantation, Hematology, Oncology
Location: Internet Activity Enduring

View Course Description

Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.

On-Demand

Pacing the Continuum of Follicular Lymphoma: Integrating Prognostic Tools and Novel Treatment Approaches

Credit: 1.0hr(s)
CME, CPE, ECMEC, MOC, NCPD

September 28, 2023 —
September 27, 2024

Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
Specialties: Lymphoma
Location: Internet Activity Enduring

View Course Description

New and emerging advancements in the treatment of follicular lymphoma (FL) are on the horizon. Are you and your clinical teams up for the challenge of testing your skill in applying the latest clinical evidence to these groundbreaking therapies? This independent satellite symposium is an engaging learning experience, where you’ll have the chance to compete against your colleagues in complex clinical cases of follicular lymphoma.